• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Clearmind Medicine Inc. - Common Shares (NQ:CMND)

    1.200 -0.050 (-4.02%)
    Streaming Delayed Price Updated: 12:25 PM EST, Mar 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Clearmind Medicine Inc. - Common Shares

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces 1-for-40 Reverse Share Split
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.